Literature DB >> 12182948

Comparative effects of angiotensin IV and two hemorphins on angiotensin-converting enzyme activity.

Ingrid Fruitier-Arnaudin1, Marie Cohen, Stéphanie Bordenave, Frédéric Sannier, Jean-Marie Piot.   

Abstract

The role of angiotensin IV (AngIV) in the regulation of angiotensin-converting enzyme (ACE) was studied in vitro. This study demonstrates that this active fragment appeared as a novel endogenous ACE inhibitor. Inhibitory kinetic studies revealed that AngIV acts as a purely competitive inhibitor with a K(i) value of 35 microM. AngIV was found to be quite resistant to ACE hydrolysis opposite to hemorphins which are both ACE inhibitors and substrates. In order to confirm a putative role of AngIV and hemorphins in the Renin-Angiotensin system (RAS) regulation, we studied their influence on AngI conversion. We noticed that 16.7 microM of both peptides decreased more than 50% of AngI conversion to AngII in vitro. The capacity of hemorphins, particularly LVVH-7, and AngIV to inhibit ACE activity here suggests a synergistic relation between these two peptides and the regulation of RAS. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182948     DOI: 10.1016/s0196-9781(02)00083-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

Review 1.  Hemoglobin-derived peptides as novel type of bioactive signaling molecules.

Authors:  Ivone Gomes; Camila S Dale; Kimbie Casten; Miriam A Geigner; Fabio C Gozzo; Emer S Ferro; Andrea S Heimann; Lakshmi A Devi
Journal:  AAPS J       Date:  2010-09-02       Impact factor: 4.009

Review 2.  Biochemical and enzymatic properties of the M1 family of aminopeptidases involved in the regulation of blood pressure.

Authors:  Masafumi Tsujimoto; Yoshikuni Goto; Masato Maruyama; Akira Hattori
Journal:  Heart Fail Rev       Date:  2007-11-13       Impact factor: 4.214

3.  Effect of Endoplasmic Reticular Stress on Free Hemoglobin Metabolism and Liver Injury.

Authors:  Sung-Hui Tseng; Ting-Yun Chang; Chun-Kuang Shih; Rong-Hong Hsieh; Chia-Wen Chen; Yi-Chun Chen; Mei-Hsiang Lin; Jung-Su Chang
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

4.  Molecular insights into the interaction of hemorphin and its targets.

Authors:  Amanat Ali; Bincy Baby; Soja Saghar Soman; Ranjit Vijayan
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

5.  Positive Modulation of Angiotensin II Type 1 Receptor-Mediated Signaling by LVV-Hemorphin-7.

Authors:  Amanat Ali; Abdulrasheed Palakkott; Arshida Ashraf; Isra Al Zamel; Bincy Baby; Ranjit Vijayan; Mohammed Akli Ayoub
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

Review 6.  Hemorphins Targeting G Protein-Coupled Receptors.

Authors:  Mohammed Akli Ayoub; Ranjit Vijayan
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07

7.  Food-Derived Hemorphins Cross Intestinal and Blood-Brain Barriers In Vitro.

Authors:  Dorothée Domenger; Benoit Cudennec; Mostafa Kouach; Véronique Touche; Christophe Landry; Jean Lesage; Fabien Gosselet; Sophie Lestavel; Jean-François Goossens; Pascal Dhulster; Rozenn Ravallec
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-10       Impact factor: 5.555

8.  Camel Hemorphins Exhibit a More Potent Angiotensin-I Converting Enzyme Inhibitory Activity than Other Mammalian Hemorphins: An In Silico and In Vitro Study.

Authors:  Amanat Ali; Seham Abdullah Rashed Alzeyoudi; Shamma Abdulla Almutawa; Alya Nasir Alnajjar; Yusra Al Dhaheri; Ranjit Vijayan
Journal:  Biomolecules       Date:  2020-03-23

Review 9.  From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase.

Authors:  Mathias Hallberg; Mats Larhed
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.